Clinical Trials Logo

Clinical Trial Details — Status: Completed

Administrative data

NCT number NCT01074385
Other study ID # NU 09CC3
Secondary ID STU00022908NCI-2
Status Completed
Phase N/A
First received February 22, 2010
Last updated September 13, 2013
Start date April 2010
Est. completion date October 2012

Study information

Verified date September 2013
Source Northwestern University
Contact n/a
Is FDA regulated No
Health authority United States: Institutional Review Board
Study type Interventional

Clinical Trial Summary

The purpose of this study is to try and improve the way that patients with colon cancer understand and cope with their illness and give them tools for talking with their loved ones and family about their illness.


Description:

Dignity Therapy is a well tolerated structured interview that helps patients reflect on who they are, what is most important to them and what lessons they have learned through life. For patients not receiving chemotherapy, Dignity Therapy gave patients more hope, more meaning in their life, and helped their families. Researchers at Northwestern University would like to see if it has the same effect in patients getting chemotherapy. We will also see if the Dignity Therapy changes patient's understanding of their disease and their medical preferences.

All study procedures will take place when participants come for a scheduled doctor's visit or to receive chemotherapy. At the first visit participants will answer a questionnaire taking approximately 15-30 minutes. Participants will then have a Dignity Therapy Session approximately 1-2 weeks later. A second Dignity Therapy Session will be scheduled again in another 1-2 weeks. Each study Dignity Therapy Session will take approximately an hour. One to two weeks later a repeat questionnaire will be filled out. Finally, a third and final questionnaire will be complete 4 weeks later.


Recruitment information / eligibility

Status Completed
Enrollment 24
Est. completion date October 2012
Est. primary completion date May 2012
Accepts healthy volunteers No
Gender Both
Age group 18 Years and older
Eligibility - Participants must be currently receiving treatment for stage IV colorectal cancer.

- Participants must have experience disease progression after their first course of treatment and are being considered for second course of treatment or have already started their second course of treatment.

- Participants must be 18 years old or older.

- All participants must have given signed, informed consent prior to registration on study.

- Participants must speak English.

Study Design

Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Supportive Care


Related Conditions & MeSH terms


Intervention

Behavioral:
Dignity Therapy
Dignity therapy is a psychotherapeutic intervention developed to address psychosocial and existential distress among terminally ill patients. Basically, it invites patients to discuss topics that matter most or how they want to be remembered. This interview is recorded and then edited and returned to the patient to be used for further reflection or for sharing with loved ones.

Locations

Country Name City State
United States Northwestern University, Northwestern Memorial Faculty Foundation Chicago Illinois

Sponsors (2)

Lead Sponsor Collaborator
Northwestern University Robert H. Lurie Cancer Center

Country where clinical trial is conducted

United States, 

Outcome

Type Measure Description Time frame Safety issue
Primary Impact of Dignity Therapy Measure the impact of dignity therapy on terminal illness acknowledgment and presence of peaceful awareness. Subjects will complete self-evaluation questionnaires at the point of registration and upon completing dignity therapy sessions. The impact will be determined by changes in the patient's baseline self-reported parameters. at baseline, 1-2 weeks after completion of dignity therapy sessions, 1 month after completion of sessions No
Secondary Measure the impact of dignity therapy on life sustaining therapy and end-of-life goals of care. Subjects will complete self-evaluation questionnaires at the point of registration and upon completing dignity therapy sessions. The impact will be determined by changes in the patient's baseline self-reported parameters. at baseline, 1-2 weeks after completion of dignity therapy sessions, 1 month after completion of dignity therapy sessions No
Secondary Establish a correlation between terminal illness acknowledgement and presence of peaceful awareness with preferences for life sustaining therapy and end-of-life goals of care. Establish a correlation between terminal illness acknowledgement and presence of peaceful awareness with preferences for life sustaining therapy and end-of-life goals of care. At Study Completion No
See also
  Status Clinical Trial Phase
Completed NCT01704703 - Study of FOLFIRI + Panitumumab Using Ultra-selection Technology of Patients With Stage IV Colorectal Cancer Refractory to Irinotecan Without Any Mutation on KRAS, PIK3Ca, BRAF and NRAS Genes Detected With Highly Sensitive Techniques Phase 2
Terminated NCT02960282 - Gut Microbiome in Fecal Samples From Patients With Metastatic Cancer Undergoing Chemotherapy or Immunotherapy
Completed NCT01998152 - Individualized Nutritional Counselling During Chemotherapy for Colorectal Cancer (COLONUT) N/A
Not yet recruiting NCT06287723 - French Assessment of MRD by Liquid Biopsies in Colorectal With Liver Metastasis Patients (FRENCH.MRD.CRLM)
Completed NCT03005002 - Durvalumab and Tremelimumab in Treating Patients With Microsatellite Stable Metastatic Colorectal Cancer to the Liver Phase 1
Completed NCT03095781 - Pembrolizumab and XL888 in Patients With Advanced Gastrointestinal Cancer Phase 1
Terminated NCT03111823 - Exercise Program During Chemotherapy in Metastatic Colorectal Cancer N/A
Active, not recruiting NCT04267575 - Canady Helios Cold Plasma Scalpel Treatment at the Surgical Margin and Macroscopic Tumor Sites N/A
Recruiting NCT03368963 - TAS102 in Combination With NAL-IRI in Advanced GI Cancers Phase 1/Phase 2
Active, not recruiting NCT04670445 - Improving Patient and Caregiver Understanding of Risks and Benefits of Immunotherapy for Advanced Cancer N/A
Active, not recruiting NCT01271582 - Investigation of Association Between UGT1A1 Polymorphisms and Irinotecan Toxicity in Korean Patients Phase 4
Active, not recruiting NCT03800602 - Nivolumab and Metformin in Patients With Treatment Refractory MSS Colorectal Cancer Phase 2
Recruiting NCT05631574 - Study of Covalent Menin Inhibitor BMF-219 in Adult Patients With KRAS Driven Non-Small Cell Lung Cancer, Pancreatic Cancer, and Colorectal Cancer Phase 1
Completed NCT03112668 - Acceptance and Commitment Therapy in Improving Well-Being in Patients With Stage III-IV Cancer and Their Partners N/A
Terminated NCT01550510 - Research Study of IV Vitamin C in Combination With Irinotecan vs Irinotecan Alone for Advanced Colorectal CA Phase 1/Phase 2
Recruiting NCT02919644 - Vaccination With Autologous Dendritic Cells Loaded With Autologous Tumour Homogenate After Curative Resection for Stage IV Colorectal Cancer. Phase 2
Completed NCT03373188 - VX15/2503 and Immunotherapy in Resectable Pancreatic and Colorectal Cancer Phase 1
Terminated NCT04044430 - Encorafenib, Binimetinib, and Nivolumab in Treating Microsatellite Stable BRAF V600E Metastatic Colorectal Cancer Phase 1
Completed NCT05025748 - Ask Questions (ASQ):Implementation of a Communication Intervention N/A
Completed NCT01722903 - Detection of CTCs in Patients Undergoing Surgery for Stage IV Colorectal Cancer N/A